JAZZ
Jazz Pharmaceuticals Plc
NASDAQ · Healthcare · Biotechnology · IE
$232.12
+1.04%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 4.7B | 4.3B | 4.1B | 3.8B | 3.7B |
| Cost of Revenue | 558.0M | 503.3M | 445.7M | 435.6M | 540.5M |
| Gross Profit | 4.2B | 3.8B | 3.6B | 3.4B | 3.1B |
| Operating Expenses | |||||
| R&D Expense | 724.9M | 782.7M | 884.0M | 849.7M | 590.5M |
| SG&A Expense | 1.6B | 1.8B | 1.4B | 1.3B | 1.4B |
| General & Admin Expense | 407.9M | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 921.4M | 947.9M | 637.3M | 627.3M | 1.2B |
| Total Operating Expenses | 3.2B | 3.5B | 2.9B | 2.8B | 3.2B |
| Cost and Expenses | 3.8B | 4.0B | 3.4B | 3.3B | 3.7B |
| Operating Income (EBIT) | 957.8M | 224.4M | 716.6M | 578.6M | (65.5M) |
| Non-Operating | |||||
| Interest Income | 23.4M | — | — | — | — |
| Interest Expense | 191.3M | 195.1M | 238.1M | 289.4M | 288.2M |
| Net Interest Income | (167.9M) | (195.1M) | (238.1M) | (289.4M) | (288.2M) |
| Other Non-Op Income/Expense | (698.2M) | (853.0M) | (247.9M) | (283.7M) | (317.2M) |
| Non-Operating Income (excl Interest) | 506.9M | 658.0M | (145.0M) | (232.1M) | (904.7M) |
| EBT (Pre-Tax Income) | 259.6M | (628.6M) | 468.7M | 294.9M | (382.7M) |
| Income Tax Expense | 53.6M | (272.4M) | (91.4M) | (119.9M) | (158.6M) |
| Bottom Line | |||||
| Net Income | 206.0M | (356.1M) | 560.1M | 414.8M | (224.1M) |
| Earnings from Cont. Ops | 206.0M | (356.1M) | 560.1M | 414.8M | (224.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 206.0M | (356.1M) | 570.9M | 439.7M | (224.1M) |
| Per Share | |||||
| Basic EPS | $3.58 | ($5.84) | $9.06 | $6.55 | ($3.58) |
| Diluted EPS | $3.07 | ($5.84) | $8.65 | $6.10 | ($3.58) |
| Revenue Per Share | $72.92 | $69.98 | $65.80 | $60.58 | $58.51 |
| Shares | |||||
| Basic Shares Outstanding | 64.7M | 61.0M | 61.8M | 63.3M | 62.5M |
| Diluted Shares Outstanding | 64.7M | 61.0M | 66.0M | 72.1M | 62.5M |
| Profitability Metrics | |||||
| EBITDA | 1.2B | 262.8M | 1.5B | 1.4B | 1.5B |
| D&A | 718.6M | 696.3M | 660.1M | 638.7M | 629.5M |
| EBIT | 450.9M | (433.5M) | 861.6M | 810.7M | 839.1M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026